Articles by Robert Rutman

As the development in cancer diagnosis and cancer treatment progresses and becomes more specific, the need for properly designed clinical trials will increase dramatically. Robert Finn's report on clinical trials1 discussed the barriers to participation, particularly low level of public interest and economic cost. There are a number of other barriers, and these will only be systematically corrected if the whole basis of these trials is reevaluated to include demographic and economic considerati

L.J. Deftos1 argues that scientific expert witnessing done by independent panels of experts appointed by judges is preferable to adversarial presentations done by experts for the defense and the plaintiff. Adversarial presentations by experts in cases involving controversial scientific evidence, as for example in the quantitative evaluation of risk, ensure the presentation of the maximum scientifically sound case for the plaintiff and equally the maximum rebuttal by the defendant. When the

Author: Robert J. Rutman, p.12 I was amazed to read the news story on the science dropout rate (Franklin Hoke, The Scientist, Jan. 25, 1993, page 1) and find no discussion of the relation to minority and female participation. Yet, as far as the future is concerned, this is the center of gravity of the problem. While the educational pipeline leading to technological careers has never had more than a fraction of the minority and female candidates needed, in recent years this fraction has declined